McConnie Randolph, Kastl Arthur
Section of Pediatric Gastroenterology, Hepatology and Nutrition, Rush University Children's Hospital, Chicago, IL, USA.
Departments of Pediatrics and Internal Medicine, Rush Medical College, 1725 W Harrison St #710, Chicago, IL, 60612, USA.
Curr Gastroenterol Rep. 2017 Aug;19(8):34. doi: 10.1007/s11894-017-0571-z.
Review tests available for detection of Clostridium difficile (C. Diff) induced disease, including when such tests should be done in children and how they should be interpreted.
Multiple tests are available for detecting disease due to C. diff. These include colonoscopy and stool analysis. Colonoscopy with biopsy is the most sensitive test for detecting the presence of colitis. The toxins produced by the C. diff. (toxin A, toxin B, and binary toxin) are the agents that cause injury and disease. Only toxin producing C. diff. Strains will cause disease. Binary toxin by itself is not thought to produce disease. Binary toxin causes disease in humans when present with toxin A and B producing bacteria, and has been implicated with fulminant life threatening disease. Stool analyses vary in sensitivity and specificity depending on the assay used. The presence of toxin producing strains of C diff. in the stool does not equate with disease. The presence of a toxin-producing bacteria or toxins (A or B) only equates with disease if diarrhea or a diseased colon (toxic megacolon, ileus, and sepsis) is present. Nucleic acid amplification testing (NAAT), when used in the stool from patients with diarrhea, appears to be the most efficient study to detect the gene that encodes for toxin A and B and thus to diagnose C. diff.-induced disease. Infants have a high carriage rate of C. diff. and are believed not to develop disease from it or its toxins. Infants should not be tested for C. difficile. The NAAT is most specific when done on patients with diarrhea with liquid stools. Testing for C. difficile should only be done on patients with diarrhea. One can assume that a patient who has no diarrhea and is not ill does not have C. diff.-induced disease. Treatment should be limited to patients with diarrhea who test positive for C. diff. toxin (A or B) or toxin-producing bacteria. Direct testing for binary toxin is not commercially available. Binary toxin is only thought to cause disease in humans when C. diff. toxin (A and B)-producing bacteria are present.
综述可用于检测艰难梭菌(C. Diff)所致疾病的检测方法,包括何时应对儿童进行此类检测以及如何解读检测结果。
有多种检测方法可用于检测艰难梭菌所致疾病。这些方法包括结肠镜检查和粪便分析。结肠镜检查及活检是检测结肠炎存在的最敏感方法。艰难梭菌产生的毒素(毒素A、毒素B和二元毒素)是导致损伤和疾病的致病因子。只有产毒素的艰难梭菌菌株会引发疾病。二元毒素本身一般不会引发疾病。二元毒素与产毒素A和B的细菌同时存在时会导致人类发病,并且与暴发性危及生命的疾病有关。粪便分析的敏感性和特异性因所采用的检测方法而异。粪便中产毒素艰难梭菌菌株的存在并不等同于疾病。只有在出现腹泻或结肠疾病(中毒性巨结肠、肠梗阻和败血症)时,产毒素细菌或毒素(A或B)的存在才等同于疾病。核酸扩增检测(NAAT)用于腹泻患者的粪便检测时,似乎是检测编码毒素A和B的基因从而诊断艰难梭菌所致疾病的最有效方法。婴儿艰难梭菌携带率很高,但一般认为不会因该菌或其毒素而发病。不应针对婴儿进行艰难梭菌检测。对稀便腹泻患者进行NAAT检测时特异性最高。艰难梭菌检测仅应针对腹泻患者进行。可以认为没有腹泻且未患病的患者不存在艰难梭菌所致疾病。治疗应仅限于艰难梭菌毒素(A或B)检测呈阳性或产毒素细菌检测呈阳性的腹泻患者。二元毒素的直接检测尚无商业可用方法。二元毒素只有在产艰难梭菌毒素(A和B)的细菌存在时才被认为会导致人类发病。